|
1
|
von der Maase H, Sengelov L, Roberts JT,
Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A and Arning
M: Long-term survival results of a randomized trial comparing
gemcitabine plus cisplatin, with methotrexate, vinblastine,
doxorubicin, plus cisplatin in patients with bladder cancer. J Clin
Oncol. 23:4602–4608. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Babaian RJ, Johnson DE, Llamas L and Ayala
AG: Metastases from transitional cell carcinoma of urinary bladder.
Urology. 16:142–144. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Clark PE, Spiess PE, Agarwal N, Bangs R,
Boorjian SA, Buyyounouski MK, Efstathiou JA, Flaig TW, Friedlander
T, Greenberg RE, et al: NCCN guidelines® insights
bladder cancer, version 2.2016 featured updates to the NCCN
guidelines. J Natl Compr Canc Netw. 14:1213–1224. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Balar AV, Galsky MD, Rosenberg JE, Powles
T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J,
Perez-Gracia JL, et al: Atezolizumab as first-line treatment in
cisplatin-ineligible patients with locally advanced and metastatic
urothelial carcinoma: A single-arm, multicentre, phase 2 trial.
Lancet. 389:67–76. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bellmunt J, de Wit R, Vaughn DJ, Fradet Y,
Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK,
et al: Pembrolizumab as second-line therapy for advanced urothelial
carcinoma. N Engl J Med. 376:1015–1026. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sharma P, Retz M, Siefker-Radtke A, Baron
A, Necchi A, Bedke J, Plimack ER, Vaena D, Grimm MO, Bracarda S, et
al: Nivolumab in metastatic urothelial carcinoma after platinum
therapy (CheckMate 275): A multicentre, single-arm, phase 2 trial.
Lancet Oncol. 18:312–322. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Petrelli F, Ghidini M, Ghidini A and
Tomasello G: Outcomes following immune checkpoint inhibitor
treatment of patients with microsatellite instability-high cancers:
A systematic review and meta-analysis. JAMA Oncol. 6:1068–1071.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Samstein RM, Lee CH, Shoushtari AN,
Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ,
Omuro A, et al: Tumor mutational load predicts survival after
immunotherapy across multiple cancer types. Nat Genet. 51:202–206.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Reck M, Rodríguez-Abreu D, Robinson AG,
Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al: Pembrolizumab versus chemotherapy for PD-L1-positive
non-small-cell lung cancer. N Engl J Med. 375:1823–1833. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bettegowda C, Sausen M, Leary RJ, Kinde I,
Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, et al:
Detection of circulating tumor DNA in early- and late-stage human
malignancies. Sci Transl Med. 6:224ra242014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Snyder A, Morrissey MP and Hellmann MD:
Use of circulating tumor DNA for cancer immunotherapy. Clin Cancer
Res. 25:6909–6915. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bardelli A and Pantel K: Liquid biopsies,
what we do not know (yet). Cancer Cell. 31:172–179. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Goldberg SB, Narayan A, Kole AJ, Decker
RH, Teysir J, Carriero NJ, Lee A, Nemati R, Nath SK, Mane SM, et
al: Early assessment of lung cancer immunotherapy response via
circulating tumor DNA. Clin Cancer Res. 24:1872–1880. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Christensen E, Birkenkamp-Demtröder K,
Sethi H, Shchegrova S, Salari R, Nordentoft I, Wu HT, Knudsen M,
Lamy P, Lindskrog SV, et al: Early detection of metastatic relapse
and monitoring of therapeutic efficacy by ultra-deep sequencing of
plasma cell-free DNA in patients with urothelial bladder carcinoma.
J Clin Oncol. 37:1547–1557. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jardim DL, Goodman A, de Melo Gagliato D
and Kurzrock R: The challenges of tumor mutational burden as an
immunotherapy biomarker. Cancer Cell. 39:154–173. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rizvi NA, Cho BC, Reinmuth N, Lee KH, Luft
A, Ahn MJ, van den Heuvel MM, Cobo M, Vicente D, Smolin A, et al:
Durvalumab with or without tremelimumab vs standard chemotherapy in
first-line treatment of metastatic non-small cell lung cancer: The
MYSTIC phase 3 randomized clinical trial. JAMA Oncol. 6:661–674.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Si H, Kuziora M, Quinn KJ, Helman E, Ye J,
Liu F, Scheuring U, Peters S, Rizvi NA, Brohawn PZ, et al: A
blood-based assay for assessment of tumor mutational burden in
first-line metastatic NSCLC treatment: Results from the MYSTIC
study. Clin Cancer Res. 27:1631–1640. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim ST, Cristescu R, Bass AJ, Kim KM,
Odegaard JI, Kim K, Liu XQ, Sher X, Jung H, Lee M, et al:
Comprehensive molecular characterization of clinical responses to
PD-1 inhibition in metastatic gastric cancer. Nat Med.
24:1449–1458. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Laukhtina E, Hassler MR, Pradere B,
Yanagisawa T, Quhal F, Rajwa P, Sari Motlagh R, König F, Pallauf M,
Kawada T, et al: Circulating tumour DNA is a strong predictor of
outcomes in patients treated with systemic therapy for urothelial
carcinoma. Eur Urol Focus. 8:1683–1686. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hellmann MD, Nathanson T, Rizvi H, Creelan
BC, Sanchez-Vega F, Ahuja A, Ni A, Novik JB, Mangarin LMB,
Abu-Akeel M, et al: Genomic features of response to combination
immunotherapy in patients with advanced non-small-cell lung cancer.
Cancer Cell. 33:843–852.e4. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sun H, Liu SY, Zhou JY, Xu JT, Zhang HK,
Yan HH, Huan JJ, Dai PP, Xu CR, Su J, et al: Specific TP53 subtype
as biomarker for immune checkpoint inhibitors in lung
adenocarcinoma. EBioMedicine. 60:1029902020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu S, Geng S, Shi N, Zhang L, Xue W, Li Y
and Jiang K: Survival prediction of patients treated with immune
checkpoint inhibitors via KRAS/TP53/EGFR-single gene mutation.
Front Pharmacol. 13:8785402022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ravi P, Ravi A, Riaz IB, Freeman D, Curran
C, Mantia C, McGregor BA, Kilbridge KL, Pan CX, Pek M, et al:
Longitudinal evaluation of circulating tumor DNA using sensitive
amplicon-based next-generation sequencing to identify resistance
mechanisms to immune checkpoint inhibitors for advanced urothelial
carcinoma. Oncologist. 27:e406–e409. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lamy A, Gobet F, Laurent M, Blanchard F,
Varin C, Moulin C, Andreou A, Frebourg T and Pfister C: Molecular
profiling of bladder tumors based on the detection of FGFR3 and
TP53 mutations. J Urol. 176:2686–2689. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Thorsson V, Gibbs DL, Brown SD, Wolf D,
Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy
JA, et al: The immune landscape of cancer. Immunity.
48:812–830.e14. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Parkinson CA, Gale D, Piskorz AM, Biggs H,
Hodgkin C, Addley H, Freeman S, Moyle P, Sala E, Sayal K, et al:
Exploratory analysis of TP53 mutations in circulating tumour DNA as
biomarkers of treatment response for patients with relapsed
high-grade serous ovarian carcinoma: A retrospective study. PLoS
Med. 13:e10021982016. View Article : Google Scholar : PubMed/NCBI
|
